:379-388 66 4 ABSTRACT Purpose | It is unknown what minimal benefit in disease-free survival older breast cancer patients require from adjuvant systemic therapy, and if this differs from that required by younger patients. We prospectively examined patients' preferences for adjuvant chemotherapy (aCT) and adjuvant hormonal therapy (aHT), factors related to minimallyrequired benefit, and patients' self-reported motivations.
INTRODUCTION
Breast cancer (BC) is a disease affecting a large proportion of women over 65 years of age.
In Western countries, approximately 40% of new cases occur in older women. 1 As the risk of developing BC increases with age and the general population is ageing, the number of older patients is expected to rise significantly. 1 In most cases of early-stage (I-II) BC, adjuvant systemic therapy is recommended in addition to primary surgery with or without post-operative radiotherapy. The addition of adjuvant chemotherapy (aCT) or adjuvant hormonal therapy (aHT) can lower the risk of BC relapse and mortality. 2 However, these therapies are associated with short-and long-term side effects which, in turn, can cause physical, psychological and social problems. 3 Therefore, the expected benefits need to be carefully weighed against its side effects. With regard to older patients, making the decision for or against systemic therapy is generally difficult. Benefits of adjuvant systemic therapy in older patients, especially those of aCT, are uncertain because of small numbers of older women in trials. 2, 4 Moreover, high rates of comorbid conditions and polypharmacy in this patient group pose additional challenges. 4 Consequently, treatment decisions in older patients should incorporate their valuation of potential benefits and side effects of treatment strategies. 5 So far, data on older patients' preferences for aCT and aHT are limited. We performed a systematic review of patients' preferences, 6 and found that most patients judged small to modest survival benefits sufficient to consider these therapies worthwhile, regardless of the consequences. A limitation of the reviewed studies was that the women surveyed had already been treated or had already received a treatment recommendation, which could have had a strong influence on their reported treatment preferences. 7 Moreover, most patients were young or middle-aged (mean/median of 36-55 years), [7] [8] [9] [10] [11] [12] and none of the studies on aHT included patients aged ≥65 years. 8, 12 A few studies have retrospectively explored factors that may affect the decisions about adjuvant systemic treatment of older patiens with BC. [13] [14] [15] These studies involved only patients aged 65-70 years and over, making it difficult to determine whether older patients place different values on benefits versus side effects of adjuvant systemic therapy than younger patients. To our knowledge, solely one retrospective study examined age differences in factors influencing treatment decisions for aCT and aHT. 16 Of the other existing studies involving patients of all ages, none specifically focused on differences in motivations between younger and older patients. [17] [18] [19] Given the growing incidence of BC in older women, it will become increasingly relevant to establish a more complete picture of treatment preferences in this patient group, and to determine whether their preferences differ from those of younger women. A better understanding of older patients' preferences and the factors that distinctively affect their preferences will assist clinicians in determining the set of treatment options relevant to older patients and in tailoring their information provision better.
The objectives of this prospective study were threefold. First, to examine whether there are differences in the benefit that younger and older patients minimally require from aCT and aHT to consider it worthwhile. Second, to determine which factors are related to the minimally-required benefit. Lastly, to examine whether motivations for and against therapy differ between younger and older patients.
METHODS

Participants
This study took place at one academic and two non-academic teaching hospitals in the Netherlands. Between January 2012 and December 2013, women aged ≥40 years with a primary invasive tumor (clinical T 1-2 ) scheduled to undergo surgery with curative intent, were included. Exclusion criteria were bilateral BC, BRCA 1/2 mutation, history of (non)invasive BC, history of other malignancies (other than non-melanoma skin cancer or cervical carcinoma in situ) within the past five years, insufficient knowledge of the Dutch language, cognitive/ mental problems, inability to participate in a telephone interview (e.g., hearing impairment), and a diagnosis of metastatic BC after resection. The Medical Ethical Committee of the Leiden University Medical Center and the institutional review boards of the participating hospitals approved the study. All participants provided informed consent.
Procedure
In a telephone interview, we determined participants' minimally-required benefit from aCT and aHT and their motivations for/against both therapies. Eligible participants were approached following their diagnosis, and they received an informed consent form and a self-administered questionnaire on socio-demographic background. After the pre-surgical consultation and before surgery, consenting patients were handed out a questionnaire about their preferred involvement in decision-making as well as information to prepare for a telephone interview scheduled after their surgery. Participants were asked to read the information right before the interview. Patients usually receive a recommendation for or against adjuvant systemic therapy based on pathological findings following surgery, during a post-surgical consultation.
To rule out that this recommendation could influence the participant's adjuvant treatment preference, the interview was held before that post-surgical consultation. Three trained interviewers conducted the interviews, strictly adhering to a script.
Measures
Minimally-required benefit and motivations for/against adjuvant systemic therapy
The minimally-required absolute benefit, in terms of additional 10-year disease-free survival, from aCT and aHT was assessed using the probability trade-off method. 20 As part of this method, we developed two hypothetical scenarios: no aCT versus aCT, and no aHT versus aHT (see Appendix A for details). The scenarios were provided to the participant and included information about the treatment strategies and the accompanying health consequences and recurrence risks. During the interview, we read aloud the information, and asked the participant to read along. Next, participants were asked to imagine that their clinician had offered them two treatment strategies. We presented a 10% difference in BC recurrence risk at 10 years between no aCT (25 out of 100 women with a recurrence) and aCT (15 out of 100 with a recurrence), and asked the participants which treatment they preferred at this benefit of aCT of 10%. The participants were asked to indicate their preference each time in subsequent comparisons, in which the absolute benefit from aCT was systematically increased or decreased, depending on their answer. If their initial preference was aCT, we searched for their minimally-required benefit between the range of 0 (no benefit) and 10%. If their initial preference was no aCT, we searched for the minimally-required benefit between the ranges of 11 and 25% (maximum benefit). Participants could indicate to refuse aCT if they considered that, for a benefit of 25%, aCT was not worthwhile. After the aCT scenario, we similarly assessed participants' preferred benefit from aHT, except that we presented a 15% difference in 10-year recurrence risk between no aHT and aHT in the initial question. At the end of each scenario, we asked participants about their motivations for their preference.
Participants' demographic and medical characteristics
The first self-report questionnaire contained questions about socio-demographic details.
Information with regard to type of surgery, comorbid conditions, and geriatric health conditions (i.e., inability to carry out daily activities, incontinence, severe sensory impairment, depression, polypharmacy, difficulty with walking 21 ) were extracted from medical records.
Comorbid conditions at the time of diagnosis were registered according to the 10 th revision of the International Classification of Diseases. 22 
Decisional role preference
We assessed participants' preferred involvement in decision-making about aCT and aHT using an adapted version of the Control Preferences Scale. 23 Participants were asked to choose one of five decisional roles, ranging from (1) the patient making the decision, (2) the patient making the decision after considering the clinician's opinion, (3) the patient making the decision jointly with the clinician, (4) the clinician making the decision after considering the patient's opinion, to (5) the clinician making the decision.
Statistical analyses
Participants were categorized into 'younger' (40-64 years) and 'older' (≥65 years) based on their age at diagnosis. The response options for decisional role preference were merged into three categories: active (1-2), shared (3), and passive (4) (5) . Comorbidity was defined as the sum of any comorbid disease (0, 1, or 2 or more diseases). Differences in patient characteristics and decisional role preferences between the groups were examined using the χ² or Fisher exact tests, as appropriate.
Participants' minimally-required benefits to accept aCT and aHT were categorized into 0%, 1-5%, 6-10%, 11-15%, 16-20%, and 21-25%. Participants who were undecided about the minimallyrequired benefit were excluded from further analyses. Younger versus older participants' minimally-required benefits and acceptance versus refusal of therapy were compared using the Fisher exact test.
Univariable logistic regression analyses were conducted to examine the association between minimally-required benefit and patient characteristics and decisional role preference. The minimally-required benefit of both aCT and aHT was dichotomized into 0-10% required benefit ('1') and 11-25% required benefit or refusal of therapy ('0'). A multivariable model was built with all significant factors (p<0.05) in univariable analysis.
Two researchers independently coded participants' motivations. Dissimilarities in coding were resolved through consensus. As this section was conducted for exploratory purposes, statistical differences in motivations between the age groups were not tested.
Analyses were conducted using SPSS version 20. A p-value below 0.05 was considered statistically significant.
RESULTS
Participants
Overall, 100 women with invasive BC were eligible for this study. Of them, 13 were not interviewed before the post-surgical consultation, and six withdrew before the interview. The reasons for withdrawal were no interest (n=3), being nervous about getting the pathology results within the next few days (n=2), and not being fully recovered from surgery (n=1).
Eighty-one participants were included in the analyses. The median time between surgery and the interview was six days (range, three to 12 days), and the telephone interview lasted on average 30 minutes (range, 10-50 minutes).
The participants' median age was 61 years (range, 42-86 years). Fifty-two (64%) participants were aged 40-64 years, and 29 (36%) were aged ≥65 years (Table 1) 
Minimally-required benefit in 10-year disease-free survival from aCT
Some younger (2/52; 4%) and older (4/29; 14%) participants could not decide which benefit they would minimally require to consider the therapy worthwhile. In the remaining participants, 92% (48/52) of the younger and 62% (18/29) of the older participants, respectively, would accept aCT, and 4% (2/52) of the younger and 24% (7/29) of the older participants would refuse aCT at the maximum absolute benefit of 25% ( Figure 1A ). Older participants refused aCT significantly more often than younger participants (p=0.005). Of those who would accept therapy, the younger participants considered aCT worthwhile at an absolute median benefit of 5% (range, 1-25%) and the older participants at an absolute median benefit of 4% (range, 0-25%). These minimally-required benefits did not significantly differ (p=0.13).
Minimally-required benefit in 10-year disease-free survival from aHT
None of the younger and 24% (7/29) of the older participants were undecided about their minimally-required benefit. In the remaining group, the majority of younger (48/52; 92%) and older (17/29; 59%) participants would accept aHT ( Figure 1B ). Eight percent (4/52) of the younger and 17% (5/29) of the older participants would refuse aHT at an absolute benefit of 25%. Overall, acceptance versus refusal rates did not significantly differ between younger and older participants (p=0.12). Of the group accepting therapy, younger and older participants considered it worthwhile at a median of 10% (range, 1-25%) and 8% (range, 0-25%) absolute benefit, respectively. These minimally-required benefits did not significantly differ (p=0.15). A p-value in bold means a significant difference between younger and older participants with respect to that variable BCS = Breast-conserving surgery; MAST = Mastectomy a Levels of education were categorized as low=completed no/primary school; intermediate=completed lower general secondary education/vocational training; or high=completed pre-university education/high vocational training/university b Presence of a geriatric health condition was defined as having one or more of the following characteristics: not able to carry out daily activities, incontinence, severe sensory impairment, depression, polypharmacy; difficulties with walking c Decisional role preferences were merged into three categories: active (the patient makes the decision alone, the patient makes the decision after considering the clinician's opinion); shared (patient makes the decision together with the clinician); and passive (the clinician makes the decision after considering the patient's opinion, the clinician makes the decision alone) d Eight participants did not fill out this question before the post-operative consultation In both scenarios, the 10-year disease-free survival without adjuvant systemic therapy was 75%, and the minimally-required benefit to accept therapy could range from 0 (no benefit) to 25% (maximum benefit) Note: pdistr=p-value for distribution; refuse=women who would not accept therapy at any benefit; do not know=women who were undecided about the minimal benefit they would require to consider the therapy worthwhile
Factors related to minimally-required benefit
Univariable logistic regression analyses showed that participants who were single/divorced/ widowed were significantly less likely to accept aCT (odds ratio [OR] 0.21; 95% confidence interval [CI] 0.08-0.59; p=0.003) or aHT (OR 0.34; 95% CI 0.13-0.92; p=0.033) for 10% benefit or less, compared to participants who were married/lived together ( Table 2 ). For aHT, there were no other significant factors besides marital status. For aCT, participants with a geriatric health condition had lower odds of accepting therapy at a 0-10% benefit (OR 0.18; 95% CI 0.06-0.50; p=0.001). Furthermore, participants who preferred an active decisional role were less likely to accept aCT at a 0-10% benefit than participants who preferred a shared decisional role A p-value in bold means a significant difference beween that group and the reference group aCT = Adjuvant chemotherapy; aHT = Adjuvant hormonal therapy; BCS = Breast-conserving surgery; MAST = Mastectomy; OR = Odds ratio; ref= reference; CI = Confidence interval a Participants who could not decide upon their minimally-required benefit were excluded (aCT, n=6; aHT, n=7) b An OR over 1 indicates a greater likelihood to accept therapy at a 0-10% benefit, an OR below 1 indicates a lower likelihood to accept therapy at a 0-10% benefit (and a greater likelihood to require a >10% benefit) c Levels of education were categorized as low=completed no/primary school; intermediate=completed lower general secondary education/vocational training; or high=completed pre-university education/high vocational training/university d Presence of a geriatric health condition was defined as having one or more of the following characteristics: not able to carry out daily activities, incontinence, severe sensory impairment, depression, polypharmacy; difficulties with walking e Decisional role preferences were merged into three categories: active (the patient makes the decision alone, the patient makes the decision after considering the clinician's opinion); shared (patient makes the decision together with the clinician); and passive (the clinician makes the decision after considering the patient's opinion, the clinician makes the decision alone) f Eight respondents did not fill out the questions about aCT and aHT before the post-operative consultation and were excluded from this analysis
Motivations in favor of or against adjuvant systemic therapy
Both younger and older participants frequently reported that the wish to survive/avoid recurrence and the treatment recommendation of their clinician were motivations in favor of aCT (Table 3 ). In the case of aHT, younger participants frequently cited the clinician's recommendation and wanting to survive/avoid recurrence as arguments for the therapy. For older participants, the clinician's recommendation was the predominant argument.
For both younger and older participants, the most often reported argument against aCT was concern about potential side effects. Older participants also commonly reported that the wish to maintain their current quality of life and independence, the negative treatment experience of others, the benefits not outweighing side effects, and their old age were arguments against aCT. Regarding aHT, both age groups frequently noted that side effects and the long duration of treatment were arguments against the therapy. Lack of social support 2 8 2 5
Long duration of treatment 2 0 40 23
No or little trust in (effectiveness) of treatment 0 0 0 5
Specific for aCT:
Frequent hospital visits for chemotherapy are a burden 2 4 --
Fear of needles 2 0 --
Specific for aHT:
Is experiencing/has experienced many/severe menopausal complaints --6 0
Taking a daily pill is a burden --2 0
Negative experience with hormones --2 0
''-'' indicates that the argument is not applicable to the therapy aCT = Adjuvant chemotherapy; aHT = Adjuvant hormonal therapy a Participants who could not decide upon their minimally-required benefit, were excluded (aCT: n=6; aHT: n=7) b Participants could indicate more than one argument
DISCUSSION
This prospective study compared the minimal benefit in 10-year disease-free survival that younger and older patients with early BC would require to consider aCT and aHT worthwhile.
Additionally, we assessed which factors were related to minimally-required benefit, and explored younger and older patients' motivations for and against these therapies. To our knowledge, this is the first study that examined preferences for aCT and aHT in older patients 24 and before patients received a recommendation for or against adjuvant systemic therapy, thereby minimizing the biasing influence of cognitive dissonance reduction. This cognitive mechanism of adaptation leads individuals to reduce inconsistencies between previous decisions (such as treatment decisions) and current beliefs. Thus, patients will tend to justify earlier decisions about how they will be treated in such ways that their current preferences are in accordance with that decision. 7 In this sample, participants did not know which treatment was indicated, and no treatment decision was yet made. We are aware that participants may already have had a treatment preference, based on clinical information they received after diagnosis (e.g., having a very large tumor), experiences from significant others, or on information found on the Internet or elsewhere. This is true also in daily practice.
Our results reveal that older participants would more often refuse aCT than younger participants, but no significant difference was found regarding aHT. However, the proportion of older participants willing to accept systemic therapy was large (three out of five women, for both aCT and aHT), and for these older women, the minimally-required benefit did not differ from that of younger women. The latter finding is in line with other studies on aCT that found no association between age and minimally-required benefit, in terms of overall [9] [10] [11] or disease-free survival, 7 but not with other studies demonstrating in contrast that higher age was related to higher minimally-required benefit from aCT 25, 26 or aHT. 26 However, our study as well as earlier studies 7, [9] [10] [11] showing no such association differ from the latter two 25, 26 regarding design and population in the following way. Firstly, in the two latter studies it was unclear whether participants could refuse therapy. Secondly, the latter studies also involved more advanced BC stages, which could lead to different treatment preferences. Based on our
results, it appears that for early-stage BC, age is not a factor in determining the minimallyrequired benefit, and that the majority of patients are willing to consider adjuvant systemic therapy. It is important for clinicians to be aware of these preferences.
Another finding was that some participants, predominantly older participants, were undecided about the minimal benefit they would require to consider adjuvant systemic therapy worthwhile. Participants primarily reported they would rely on the treatment advice of their clinician. It is important that clinicians themselves are aware of this finding, and they should try to ensure that information provision is clear and tailored to the needs of the patient. Additionally, patients should be made aware that they should voice their preferences and concerns.
Another finding was that being single, divorced, or widowed, having a geriatric health condition, and having a preference for an active decisional role predicted patients' preference for aCT. Women who were single/divorced/widowed had a five times higher odds of requiring a large benefit than women who were married/living together. This may be explained by either not having a partner for whom to consider a treatment worthwhile ("to live for"), or by lack of support from a partner during treatment. If a patient has one or more geriatric health conditions, she might be more likely to think that she might not cope with the side effects of adjuvant systemic therapy, and thus her minimally-required benefit should be higher to make it worthwhile. The association with role preference may be explained by two mechanisms with a different causal direction. On the one hand, patients who do not want aCT may want to be actively involved to ensure that no overtreatment occurs. That is, patients' existing treatment preference may determine their role preference. On the other hand, it has been found that patients who are more active, following the use of a decision aid, tend to choose more conservative treatment, 27 implying that decisional role may explain treatment preference.
As expected, the predominant motivation in favor of aCT was to survive/avoid recurrence, irrespective of age. Nevertheless, older participants seemed to value the clinician's recommendation more compared to younger participants. These two factors have often been noted in previous studies concerning older patients' decision-making about aCT 13, 14 and about treatment for BC in general. 15, 28 Further, our study indicated that motivations against aCT largely differed between younger and older participants. Both groups frequently reported concern about side effects as a motivation. Additionally, older participants reported the wish to maintain their current quality of life and independence and the belief that benefits do not outweigh side effects as concerns about aCT. As these concerns are specific to older patients, more focus should be placed on quality of life and independence when discussing treatment consequences, and sufficient information should be provided to help develop realistic expectations on side effects of aCT. This will better support older patients in developing an informed treatment preference. Interestingly, although age was not a factor in determining the minimally-required benefit to accept therapy, it was an important argument for women in deciding for or against adjuvant systemic therapy. The most striking observation was that older participants more frequently stated that their old age was an argument against aCT.
The motivations for aHT were similar to those found for aCT, except that the wish to survive/ avoid recurrence was less frequently reported. An explanation may be that participants generally know less about this treatment compared with aCT, and thus possibly doubt or underestimate the effectiveness of aHT. The wish to survive/avoid recurrence and the clinician's recommendation were valued equally in younger participants. This was not found for older participants who considered the clinician's recommendation most important.
With regard to arguments against aHT, no overt differences were found in the predominant motivations between the age groups.
Some limitations of this study need to be noted. Participants were approached before they actually faced a decision. Although they probably would be confronted with this decision, the preference they reported here might still differ from their preference once they had received a recommendation. Further, fewer older participants than anticipated could be included in the study. This was owing to the fact that primarily older participants were excluded based on the exclusion criterion of having a previous malignancy (11 older compared with 2 younger women). Nevertheless, comparison of our older participants with older patients with earlystage invasive BC enrolled in a population-based cohort study in the Netherlands 29 showed that our sample was compared favorably with the average older woman with BC with regard to median age and presence of comorbid and geriatric conditions. Finally, because our sample was small, further investigation about younger and older participants' preferences for aHT in a larger sample is required.
Conclusion
This prospective study revealed that whereas older participants were less willing to undergo aCT than younger participants, no significant difference was found for aHT. Still, a majority of older participants would accept both therapies, and these women required similar benefits in 10-year disease-free survival as younger women. 30, 31 This ageism may partially explain why older patients more often receive suboptimal therapy than younger patients, which might then be associated with lower survival rates. 32 • Our prospective study has generated new knowledge that can be of help when making adjuvant treatment decisions with older patients. We found that the proportion of older women that would accept adjuvant systemic therapy was large, and for these women the minimally-required benefit for aCT and aHT did not differ from that of younger women. Also, we found a large variation in preferences within the older group, suggesting that each individual older patient may value the benefits and side effects of treatment strategies differently.
• It is necessary to involve older patients in the decision-making process. This requires patients to be made aware that adjuvant systemic therapy is an option. Next, the benefits and side effects involved, including the associated uncertainty given the individual's biological age, should be discussed. It is essential to explicitly explore the patient's consideration as to whether the expected benefit is worth the side effects. 
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APPENDIX A. Hypothetical scenario A.1: no adjuvant chemotherapy versus adjuvant chemotherapy; and hypothetical scenario A.2: no adjuvant hormonal therapy versus adjuvant hormonal therapy
The numbers represent the order in which the information about the treatment strategies was read aloud. Health consequences and side effects were based on a previous study about patient preferences (in the case of adjuvant chemotherapy only), 7 patient education brochures of the Dutch Cancer Society, 34, 35 and expertise of two medical oncologists. Recurrence probabilities with and without adjuvant systemic therapy at 10 years were based on Early Breast Cancer Trialists' Collaborative Group data 36, 37 and the Dutch treatment guidelines for BC. 38 The time period of 10 years differs from earlier studies, 7-9,11,12 but reflects current clinical practice. The treatment strategies were listed next to each other to ease comparability, and a combination of frequency formats and bar graphs was used to present the recurrence probabilities. This format was pilot-tested (face-to-face and by phone) among two healthy women and 23 patients, to assess readability, ease of understanding, and the level of distress the information might provoke. Based on the feedback, the wording of the interview questions was rephrased to improve understanding.
TREATMENT
HEALTH CONSEQUENCES AND SIDE EFFECTS
PROBABILITY OF RECURRENCE AT 10 YEARS
Chemotherapy No chemotherapy
The treatment consists of surgery (and possibly irradiation), followed by chemotherapy.
In most cases, chemotherapy is given once every three weeks for up to 6 months. It is administered by intravenous drip in the arm at the hospital, and each session lasts a few hours.
After chemotherapy check-ups with the treating specialist take place.
Both the disease and surgery (and irradiation) can cause physical, psychological and/or social problems.
Additionally chemotherapy can cause side effects, such as:
Hair loss, tiredness, feeling sick and vomiting, muscle and joint pain, diarrhea or constipation, decrease in the number of red blood cells, increased chance of infections, sores in the mouth, feeling of numbness or pins and needles, loss of appetite, skin rashes, itching, sore eyes, menopausal symptoms, infertility and (rarely) heart problems
The intensity of these side effects is impossible to predict; this varies from person to person.
The treatment consists of surgery (and possibly irradiation).
After surgery check-ups with the treating specialist take place.
Of the 100 women who do not undergo chemotherapy: 75 will have no recurrence of the disease 25 will have a recurrence of the disease Of the 100 women who do undergo chemotherapy: 75 will have no recurrence of the disease 10 will benefit from chemotherapy 15 will have a recurrence of the disease 
